ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1290

Inflammation Is More Prominent Than Joint Damage at Initial Visits of Patients with Inflammatory Arthritides, but Organ Damage and Patient Distress Are as Prominent in Overall Rheumatology Care: Data from a Feasible Physician RheuMetric Checklist

Juan Schmukler1, Tengfei Li2, Joel Block1 and Theodore Pincus1, 1Rush University Medical Center, Chicago, IL, 2Georgetown University, Washington, DC

Meeting: ACR Convergence 2022

Keywords: Comorbidity, Disease Activity, Outcome measures

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Measures and Measurement of Healthcare Quality Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Most widely-used rheumatology indices, e.g., DAS28, CDAI, SLEDAI, ASDAS, DAPSA, reflect the mission of rheumatologists to control inflammatory activity (INF) to prevent subsequent organ damage. These indices function effectively in selected patients in clinical trials and other clinical research, which generally include only a small minority of patients with any diagnosis. In routine care of unselected patients, the indices may be elevated in many patients by comorbid organ damage (DAM) and/or patient distress (STR), despite little or no inflammatory activity. Quantitative assessment of DAM and STR, as well as INF, is provided by a RheuMetric checklist, with 4 0-10 visual numeric scales (VNS) for physician global assessment (DOCGL), and an estimate of the proportion of DOCGL attributed to INF, DAM, and STR. We analyzed RheuMetric scores in patients at their initial visits and return visits at a rheumatology academic setting

Methods: A retrospective cross-sectional study was performed of RheuMetric checklist 0-10 VNS estimates for DOCGL and estimates of %INF, %DAM, and %STR (total=100%) completed in routine care by the treating rheumatologists. Mean levels of these estimates were analyzed according to primary diagnosis or diagnostic category of inflammatory rheumatic diseases (RA, SLE, SpA, vasculitis and gout), classified as at initial visits or return visits, using descriptive and chi-square statistics

Results: RheuMetric estimates required about 15 seconds to complete. At initial visits, mean DOCGL was 3.9 in all patients (range 3.0–4.9) (Table), attributed 62% to INF in inflammatory diseases, 72% to DAM in osteoarthritis (OA), and 74% to STR in fibromyalgia (FM) (p< 0.001), supporting face validity. In all patients at first visits, INF, DAM, and STR were estimated at 36%, 36%, and 28%, respectively (Table). At return visits, mean DOCGL was marginally lower (better) in inflammatory diseases, 3.7 vs 4.3, but similar in other diagnosis groups, 4.1 vs 3.9 in all patients. At return visits, mean DOCGL was attributed 33% to INF and 49% to DAM in inflammatory diseases, 69% to DAM in OA, and 68% to STR in FM(p< 0.001), while estimates in all patients of INF, DAM, and STR were 22%, 51% and 28%(p=0.05 vs initial visits), respectively (Table). Estimates of % DAM were increased in inflammatory disease diseases, other diagnoses and all patients (p< 0.05) (Table)

Conclusion: RheuMetric physician estimates for inflammation, damage, and patient distress have face validity as % INF, % DAM in OA, and % STR in FM. In patients with inflammatory diseases, DOCGL was attributed more to INF than DAM at first visits, but more to DAM than INF at return visits, reflecting highly effective anti-inflammatory treatments. In all patients, %INF, %DAM, and %STR were similar at first visits, but 50% DAM, 22% INF and 28% STR at return visits. While these findings may be expected, quantitative estimates of damage and distress, in addition to inflammation, may add to clinical decisions and explain why many patients may remain in moderate or high activity according to conventional rheumatology indices, which though considered to be sensitive only to inflammation, also reflect damage and distress.

Supporting image 1

Table: Cross sectional analysis of mean (standard deviation) for 0_10 physician global estimate (DOCGL) and % of DOCGL attributed to inflammation (%INF), damage (%DAM), and patient distress (%STR) (Total=100%) at 244 initial visits compared to 319 return visits according to
diagnosis or diagnostic group

Δ p<0.001 at both initial and return visits. *p<0.001 vs initial visits, ◊p=0.05 vs initial visits


Disclosures: J. Schmukler, None; T. Li, None; J. Block, None; T. Pincus, Medical History Services, LLC, Medical History Services LLC.

To cite this abstract in AMA style:

Schmukler J, Li T, Block J, Pincus T. Inflammation Is More Prominent Than Joint Damage at Initial Visits of Patients with Inflammatory Arthritides, but Organ Damage and Patient Distress Are as Prominent in Overall Rheumatology Care: Data from a Feasible Physician RheuMetric Checklist [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/inflammation-is-more-prominent-than-joint-damage-at-initial-visits-of-patients-with-inflammatory-arthritides-but-organ-damage-and-patient-distress-are-as-prominent-in-overall-rheumatology-care-data/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inflammation-is-more-prominent-than-joint-damage-at-initial-visits-of-patients-with-inflammatory-arthritides-but-organ-damage-and-patient-distress-are-as-prominent-in-overall-rheumatology-care-data/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology